These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21673038)

  • 1. Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania.
    West SK; Munoz B; Mkocha H; Gaydos CA; Quinn TC
    J Infect Dis; 2011 Jul; 204(2):268-73. PubMed ID: 21673038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
    West SK; Munoz B; Mkocha H; Gaydos C; Quinn T
    Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1492-7. PubMed ID: 17389476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma?: PRET Ziada trial results.
    Yohannan J; Munoz B; Mkocha H; Gaydos CA; Bailey R; Lietman TA; Quinn T; West SK
    JAMA Ophthalmol; 2013 Apr; 131(4):431-6. PubMed ID: 23392481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass azithromycin distribution for hyperendemic trachoma following a cluster-randomized trial: A continuation study of randomly reassigned subclusters (TANA II).
    Keenan JD; Tadesse Z; Gebresillasie S; Shiferaw A; Zerihun M; Emerson PM; Callahan K; Cotter SY; Stoller NE; Porco TC; Oldenburg CE; Lietman TM
    PLoS Med; 2018 Aug; 15(8):e1002633. PubMed ID: 30106956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.
    West SK; Munoz B; Mkocha H; Holland MJ; Aguirre A; Solomon AW; Foster A; Bailey RL; Mabey DC
    Lancet; 2005 Oct; 366(9493):1296-300. PubMed ID: 16214600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania.
    Cajas-Monson LC; Mkocha H; Muñoz B; Quinn TC; Gaydos CA; West SK
    PLoS Negl Trop Dis; 2011 Mar; 5(3):e978. PubMed ID: 21423645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?
    West SK; Moncada J; Munoz B; Mkocha H; Storey P; Hardick J; Gaydos CA; Quinn TC; Schachter J
    J Infect Dis; 2014 Jul; 210(1):65-71. PubMed ID: 24446528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass treatment with single-dose azithromycin for trachoma.
    Solomon AW; Holland MJ; Alexander ND; Massae PA; Aguirre A; Natividad-Sancho A; Molina S; Safari S; Shao JF; Courtright P; Peeling RW; West SK; Bailey RL; Foster A; Mabey DC
    N Engl J Med; 2004 Nov; 351(19):1962-71. PubMed ID: 15525721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children.
    Lee JS; Muñoz BE; Mkocha H; Gaydos CA; Quinn TC; West SK
    PLoS Negl Trop Dis; 2014 Apr; 8(4):e2761. PubMed ID: 24722392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.
    Stare D; Harding-Esch E; Munoz B; Bailey R; Mabey D; Holland M; Gaydos C; West S
    Ophthalmic Epidemiol; 2011 Feb; 18(1):20-9. PubMed ID: 21275593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial.
    Amza A; Kadri B; Nassirou B; Stoller NE; Yu SN; Zhou Z; Chin S; West SK; Bailey RL; Mabey DC; Keenan JD; Porco TC; Lietman TM; Gaynor BD;
    PLoS Negl Trop Dis; 2012; 6(4):e1586. PubMed ID: 22545165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.
    Harding-Esch EM; Sillah A; Edwards T; Burr SE; Hart JD; Joof H; Laye M; Makalo P; Manjang A; Molina S; Sarr-Sissoho I; Quinn TC; Lietman T; Holland MJ; Mabey D; West SK; Bailey R;
    PLoS Negl Trop Dis; 2013; 7(6):e2115. PubMed ID: 23785525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation (ASANTE) Trial: Design and Baseline Characteristics.
    Ervin AM; Mkocha H; Munoz B; Dreger K; Dize L; Gaydos C; Quinn TC; West SK
    Ophthalmic Epidemiol; 2016 Dec; 23(6):347-353. PubMed ID: 27820670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of Mass Azithromycin Distribution for Ocular Chlamydia in a Trachoma Endemic Region of Ethiopia: A Cluster Randomized Trial.
    Lietman TM; Ayele B; Gebre T; Zerihun M; Tadesse Z; Emerson PM; Nash SD; Porco TC; Keenan JD; Oldenburg CE
    Am J Ophthalmol; 2020 Jun; 214():143-150. PubMed ID: 32171768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.
    Last AR; Burr SE; Harding-Esch E; Cassama E; Nabicassa M; Roberts CH; Mabey DCW; Holland MJ; Bailey RL
    Parasit Vectors; 2017 Dec; 10(1):624. PubMed ID: 29282126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of Niger.
    Amza A; Kadri B; Nassirou B; Cotter SY; Stoller NE; West SK; Bailey RL; Porco TC; Keenan JD; Lietman TM; Oldenburg CE
    Ophthalmic Epidemiol; 2019 Aug; 26(4):231-237. PubMed ID: 30957594
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control.
    West SK; Munoz BE; Mkocha H; Gaydos C; Quinn T
    Ophthalmic Epidemiol; 2015; 22(3):170-5. PubMed ID: 26158574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal.
    Harding-Esch EM; Holland MJ; Schémann JF; Sillah A; Sarr B; Christerson L; Pickering H; Molina-Gonzalez S; Sarr I; Andreasen AA; Jeffries D; Grundy C; Mabey DCW; Herrmann B; Bailey RL
    Parasit Vectors; 2019 Oct; 12(1):497. PubMed ID: 31640755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions.
    Biebesheimer JB; House J; Hong KC; Lakew T; Alemayehu W; Zhou Z; Moncada J; Rogér A; Keenan J; Gaynor BD; Schachter J; Lietman TM
    Ophthalmology; 2009 Nov; 116(11):2047-50. PubMed ID: 19744717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma.
    Keenan JD; Ayele B; Gebre T; Moncada J; Stoller NE; Zhou Z; Porco TC; McCulloch CE; Gaynor BD; Emerson PM; Schachter J; Lietman TM
    Clin Infect Dis; 2012 Jan; 54(2):253-6. PubMed ID: 22095569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.